Showing results (41-50 of 68) with videos related to
Sort By:
Pageof 7
The New England Journal of Medicine|June 2, 2018
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's MacroglobulinemiaMeletios A Dimopoulos, Alessandra Tedeschi, Judith Trotman, et al.Blood|January 18, 2006
Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemiaSteven P Treon, Morie A Gertz, Meletios Dimopoulos, et al.The Lancet. Haematology|October 22, 2020
Consensus treatment recommendations from the tenth International Workshop for Waldenström MacroglobulinaemiaJorge J Castillo, Ranjana H Advani, Andrew R Branagan, et al.Leukemia|May 24, 2019
A revised international prognostic score system for Waldenström's macroglobulinemiaEfstathios Kastritis, Pierre Morel, Alain Duhamel, et al.Hemasphere|August 18, 2020
Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 PandemicDipti Talaulikar, Ranjana H Advani, Andrew R Branagan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2021
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE StudyChristian Buske, Alessandra Tedeschi, Judith Trotman, et al.Leukemia Research|March 26, 2015
Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemiaMark C Lanasa, Leslie Andritsos, Jennifer R Brown, et al.Future Oncology (London, England)|February 23, 2023
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemiaChristian Buske, Alessandra Tedeschi, Judith Trotman, et al.Cancer Medicine|May 9, 2019
Gain of the short arm of chromosome 2 (2p gain) has a significant role in drug-resistant chronic lymphocytic leukemiaFotini Kostopoulou, Clementine Gabillaud, Elise Chapiro, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2016
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II TrialRalf U Trappe, Daan Dierickx, Heiner Zimmermann, et al.Pageof 7